Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAA) is a blank-check company focused on the domestic pharmaceutical and life sciences sector, targeting businesses involved in U.S.-based drug manufacturing and development. The SPAC completed its IPO in 2021 and filed a definitive proxy statement (DEF 14A) with the SEC on April 14, 2026, indicating that shareholders have been called to vote on a proposed business combination. The filing, bearing accession number 0001213900-26-043527, reflects the company's active progress toward completing a merger transaction in the healthcare and pharmaceutical space. Visit SpacDesk and sign up for full data, filings, and deal analytics on DMAA and hundreds of other active SPACs.